Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus
Trial Timeline
Jul 4, 2018 → May 15, 2019
NCT ID
NCT04022993About Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution
Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insulin RinGlar, 100 Units/mL Subcutaneous Solution is a phase 3 stage product being developed by GEROPHARM for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT04022993. Target conditions include Diabetes Mellitus, Type 1, Diabetes Mellitus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04022993 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1